news
Reimbursement Parity Advances Patient Access and Will Help More Patients Avoid the Pain, Complications, and Repeat Surgeries Common in the $1 Billion Legacy Sacral Neuromodulation (SNM) Market Served by Boston Scientific and Medtronic SAN JOSE, Calif., July 8, 2026 /PRNewswire/ — Neuspera Medical today highlighted that the Centers for Medicare & Medicaid Services (CMS) has confirmed the assignment of […]
94% of Test-Phase Responders Achieved Significant Symptom Relief with Zero Serious Device-Related Adverse Events New Data Suggests 30 Minutes of Daily iSNM Therapy Provides UUI Symptom Relief SAN JOSE, Calif., March 5, 2026 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, announced positive 12-month outcomes1 from its pivotal trial of the Neuspera […]
Patient Struggled with SNM Battery Pain and Complications; Reports Full Complication Relief Following Implant of Neuspera’s SNM Therapy New Patient Registry to Track Outcomes of SNM to iSNM Procedures SAN JOSE, Calif., Feb. 10, 2026 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced a milestone patient revision from a […]
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved its integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence (UUI). Neuspera’s iSNM system offers patients with UUI an alternative to […]
Pivotal Study Data Show Comparable “Gold Standard” Efficacy to Traditional Sacral Neuromodulation (SNM) Devices – Eliminating Burdens of a Battery Implant SAN JOSE, Calif., Feb. 26, 2025 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of wireless energy technology powering the future of bioelectronic medicine, today announced six-month pivotal clinical trial results showing that the efficacy of its battery-free percutaneous sacral […]
The primary endpoint results of the Neuspera Phase II SANS UUI clinical study will be presented during the annual winter meeting of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), February 26 – March 1, 2025, in Rancho Mirage, California. These pivotal trial results will support Neuspera’s FDA PMA submission for U.S. […]
Trial of SNM device for urinary urgency incontinence progresses. Check out the information in Urology Times, September 2024. Volume 52, Number 09, Page 10. Read the full article here.
Did you know that this week is Urology Week 2024? To commemorate the occasion, MassDevice published an article on the top 10 urology device stories of 2024 so far and it featured our Series D round! LinkedIn X
The seasoned life sciences executive will play a key role as the company completes the regulatory process and prepares for commercialization of its Neuspera SNM System SAN JOSE, Calif., Sept. 12, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System, announced today that Bunty Banerjee has joined the company as its first Chief Operating […]
We’re excited to welcome two new members to our Neuspera team: Douglas Sullivan as Supply Chain Director and Jeff Siegel, CPA as Controller. We are grateful to have their expertise on the team as we continue working to improve sacral neuromodulation options for treating OAB!